The KRAS glycine-to-cysteine mutation (KRAS G12C) comprises approximately 44% of KRAS mutations in NSCLC, with mutant KRASG12C present in approximately 13% of all patients with lung adenocarcinoma. Mutant KRAS has been an oncogenic target for decades, but no viable therapeutic agents were ...
This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics and Activity of HS-10370 in Combination With Other Anti-cancer Therapies in patients with KRAS G12C mutation advanced or metastatic solid tumors, especially in non-Small cell lung cancer (NSCLC) . 开始日期20...
2. Skoulidis F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021; 384: 2371-2381. 3. Ninomaru T. et al. Lazarus response to tepotinib for leptomeningeal metastases in a patient with MET exon 14 skipping mutation-positive lung adenocarcinoma: case r...
2. Skoulidis F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021; 384: 2371-2381. 3. Ninomaru T. et al. Lazarus response to tepotinib for leptomeningeal metastases in a patient with MET exon 14 skipping mutation-positive lung adenocarcinoma: case r...
As of May 28, 2021, sotorasib has achieved US FDA approval for patients with KRAS G12C mutant lung cancer after one line of a prior therapy.Similar content being viewed by others Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration Article 13 January 2020 ...
Small-molecule inhibitors targeting mutant KRASG12C demonstrated promising anti-tumor effect in patients with non-small cell lung cancer harboring KRASG12C mutation, while the intrinsic and acquired drug resistance occurred frequently and might be inevitable. Unlike the protein-level inhibition approach,...
Define KRAS. KRAS synonyms, KRAS pronunciation, KRAS translation, English dictionary definition of KRAS. Isthmus of A strip of land, about 65 km wide at its narrowest point, linking the Malay Peninsula with the Asian mainland. American Heritage® Dicti
EP: 12.Novel Therapy for NSCLC With EGFR Exon 20 Insertion Mutation Now Viewing EP: 13.Novel Therapy for NSCLC With KRAS G12C Mutation EP: 14.Novel Therapy for NSCLC With ALK Rearrangements EP: 15.Non–Small Cell Lung Cancer: Targeted Agents for HER2, METExon14 and RET Alterations EP: ...
ASCO、NCCN及CSCO指南均对转移性胰腺癌的临床治疗指南进行了更新,将NTRK抑制剂,PD1抗体和PARP抑制剂奥拉帕利列入二线治疗方案,显示了胰腺癌的临床治疗已正式进入精准治疗时代;与此同时,KRAS G12C抑制剂sotorasib在2期临床试验中显示了惊人的治疗效果...
2021年5月,KRAS抑制剂Lumakras获得美国FDA批准,成为40年来率先获批针对KRAS基因突变的靶向药物[3];2022年第二款KRAS G12C抑制剂Krazati(Adagrasib)上市,越来越多的研究人员将目光放到针对KRAS靶点的靶向治疗上[7]。 ▲图源:创客贴 近日,...